| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/26/2006 | WO2006009819A1 Inhibitors of cholesteryl ester transfer protien |
| 01/26/2006 | WO2006009769A1 Modified release formulation of memantine |
| 01/26/2006 | WO2006009755A2 Azaindoles modulating c-kit activity and uses therefor |
| 01/26/2006 | WO2006009736A1 Processes for preparing gonadotropin releasing hormone receptor antagonists |
| 01/26/2006 | WO2006009726A2 Substituted urea derivatives for treating cardiac diseases |
| 01/26/2006 | WO2006009718A2 Methods for treating or preventing erectile dysfunction or urinary incontinence |
| 01/26/2006 | WO2006009698A2 Antagonizing an adenosine a2a receptor to amelioriate one or more components of addictive behavior |
| 01/26/2006 | WO2006009653A1 Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase |
| 01/26/2006 | WO2006009602A2 Multiple ppi dosage form |
| 01/26/2006 | WO2006009568A2 Peripherally-acting vasodilators |
| 01/26/2006 | WO2006009465A2 Composition comprising protein material and non-oxidizable fatty acid entities |
| 01/26/2006 | WO2006009464A2 Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities |
| 01/26/2006 | WO2006009436A1 Use of sphingolipids for prevention and treatment of atherosclerosis |
| 01/26/2006 | WO2006009325A1 Metalloprotease inhibitor |
| 01/26/2006 | WO2006009209A1 Preventive or therapeutic agent for chronic inflammatory lung disease |
| 01/26/2006 | WO2006009119A1 Process for production of polysubstituted cyclobutanes and polysubstituted cyclobutenes |
| 01/26/2006 | WO2006009093A1 Medicament for preventing and/or treating sleep disorder |
| 01/26/2006 | WO2006009092A1 Method of effectively using medicine and method concerning prevention of side effect |
| 01/26/2006 | WO2006009054A1 Phenethylnicotinamide compound |
| 01/26/2006 | WO2006008656A2 Oatp-c gene c463a polymorphism underlies variable response of statin therapy |
| 01/26/2006 | WO2006008649A1 Anti-sense polynucleotide therapy for gastrin-promoted tumors |
| 01/26/2006 | WO2006008640A1 Non-aqueous suspension containing a drug having an unpleasant taste |
| 01/26/2006 | WO2006008636A2 Processes for the preparation of zolpidem and its hemitartrate |
| 01/26/2006 | WO2006008558A1 Arylacetic acids and related compounds for treatment of alzheimer’s disease |
| 01/26/2006 | WO2006008556A1 Imidazole and thiazole derivatives as antiviral agents |
| 01/26/2006 | WO2006008552A1 Hydrating composition |
| 01/26/2006 | WO2006008545A2 Thiazole and isothiazole derivatives as protein kinase inhibitors |
| 01/26/2006 | WO2006008512A2 Anti-histaminic composition |
| 01/26/2006 | WO2006008503A1 Pyrimidothiophene compounds |
| 01/26/2006 | WO2006008386A1 Bioactive biomaterials for controlled delivery of active principles |
| 01/26/2006 | WO2006008354A1 Use of a pharmaceutical composition comprising calcitriol and clobetasol propionate for the treatment of psoriasis |
| 01/26/2006 | WO2006008316A2 Selective inhibitors of human corticosteroid syntheses |
| 01/26/2006 | WO2006008270A1 Use of compounds containing thiol groups as an efflux pump inhibitor |
| 01/26/2006 | WO2006008213A1 Medicaments for inhalation comprising pde iv inhibitors and enantiomercally pure glycopyrrolate salts |
| 01/26/2006 | WO2006008133A2 Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
| 01/26/2006 | WO2006008115A1 Diterpenic labdans as immunostimulants for treating infectious diseases |
| 01/26/2006 | WO2006008092A1 Use of a steroid for enhancement of skin permeability |
| 01/26/2006 | WO2006008091A2 Oxidative degradation products of atorvastatin calcium |
| 01/26/2006 | WO2006008082A1 Pharmaceutical compositions for the treatment of leishmaniasis |
| 01/26/2006 | WO2006008038A1 Methylidene-d-xylopyranosyl-substituted and oxo-d-xylopyranosyl-substituted phenyls, medicaments containing these compounds, their use and method for the production thereof |
| 01/26/2006 | WO2006007959A1 Diphenylamine-substituted salicylthiazole derivatives and related compounds as phosphotyrosine phosphatase 1b (ptp1b) inhibitors for using as blood-sugar decreasing active ingredients for treating diabetes |
| 01/26/2006 | WO2006007910A1 Use of non-glucocorticoid steroids for the treatment of muscular dystrophy |
| 01/26/2006 | WO2006007881A2 New pharmaceutical compositions based on fluorenecarboxyclic acid esters and soluble tnf receptor fusion proteins |
| 01/26/2006 | WO2006007864A1 Treating neurodegenerative conditions |
| 01/26/2006 | WO2005121102A3 Factor viia inhibitor |
| 01/26/2006 | WO2005120573A3 Cationic bacteriochlorophyll derivatives and uses thereof |
| 01/26/2006 | WO2005120539A3 Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| 01/26/2006 | WO2005118579A3 Thiazole derivatives as chemokine receptor antagonists |
| 01/26/2006 | WO2005116009B1 Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors |
| 01/26/2006 | WO2005111020A3 Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4 |
| 01/26/2006 | WO2005110002A3 Anti-inflammatory and anticeptic suppository exhibiting a regeneration effect |
| 01/26/2006 | WO2005107809A3 Antimycobacterial pharmaceutical composition comprising an antitubercular drug |
| 01/26/2006 | WO2005105766A3 Arylphenylamino-and arylphenylether-sulfide derivatives, useful for the treatment of inflammatory and immune diseases, and pharmaceutical compositions containing them |
| 01/26/2006 | WO2005099693A3 Methods and materials for assessing prostate cancer therapies and compounds |
| 01/26/2006 | WO2005097788A3 Sulfonamides and uses thereof |
| 01/26/2006 | WO2005097787A3 Novel benzothiazoles and the use thereof as medicaments |
| 01/26/2006 | WO2005097161A3 Gpe and g-2mepe, caffeine and alkanol for treatment of cns injury |
| 01/26/2006 | WO2005097134A3 Quinazoline based protein kinase inhibitors |
| 01/26/2006 | WO2005097119A3 Pten inhibitors |
| 01/26/2006 | WO2005094836A3 Use of loteprednol etabonate for the treatment of dry eye |
| 01/26/2006 | WO2005094384A3 Methods and compositions for treatment of ion imbalances |
| 01/26/2006 | WO2005092877A8 Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof |
| 01/26/2006 | WO2005092304A3 Antifungal agents |
| 01/26/2006 | WO2005089515A9 Methods for the treatment of synucleinopathies |
| 01/26/2006 | WO2005086941A3 Process and composition for teating viral infections |
| 01/26/2006 | WO2005079868A3 Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses |
| 01/26/2006 | WO2005079747A8 Pharmaceutical preparation for the oral cavity |
| 01/26/2006 | WO2005077922A3 Process for the preparation of substituted triazole compounds |
| 01/26/2006 | WO2005077463A3 Ligand for a monoamine receptor or transporter for treating addiction or dependence |
| 01/26/2006 | WO2005077343A3 Novel drugs and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases |
| 01/26/2006 | WO2005073236A3 Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors |
| 01/26/2006 | WO2005070392A3 Non-lamellar compositions of dioleoyl phosphatidylethanolamine and polysorbate 80 |
| 01/26/2006 | WO2005066197A3 Inhibitors of methionine aminopeptidase-2 and uses thereof |
| 01/26/2006 | WO2005063297A3 Melatonin combination therapy for improving sleep quality |
| 01/26/2006 | WO2005061476A3 Aroylfuranes and aroylthiophenes |
| 01/26/2006 | WO2005056522A3 Indole compounds |
| 01/26/2006 | WO2005048927A3 Methods and reagents for the treatment of inflammatory disorders |
| 01/26/2006 | WO2005037205A3 Haloacetamide and azide substituted compounds and methods of use thereof |
| 01/26/2006 | WO2005027855A3 Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors |
| 01/26/2006 | WO2005009354A3 Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury |
| 01/26/2006 | WO2004100874A3 Androgen receptor modulators and methods of use thereof |
| 01/26/2006 | WO2004071406A3 Creatine ester anti-inflammatory compounds and formulations |
| 01/26/2006 | WO2004045507A3 Anti-angiogenic uses of il-6 antagonists |
| 01/26/2006 | WO2001085170A9 Peptide deformylase inhibitors |
| 01/26/2006 | US20060021088 Identification of novel e2f target genes and use thereof |
| 01/26/2006 | US20060020138 E.g., 3-arylmethyl-7-hydroxy-coumarins as intermediates; affects both the Tumor Necrosis Factor alpha level and transcription activity of NuclearFactor kappa Beta; antiimmunoinflammatory agents and autoimmune properties; antiarthritis agents; rheummatic diseases; osteoporosis; leukemia |
| 01/26/2006 | US20060020137 Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| 01/26/2006 | US20060020132 high binding efficiencies between D3 and D2 dopaminergic receptor subtypes; drug abuse, drug dependence |
| 01/26/2006 | US20060020128 Therapy-enhancing glucan |
| 01/26/2006 | US20060020046 Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies |
| 01/26/2006 | US20060020045 Methods and compositions for treating inflammatory disorders of the gastrointestinal tract |
| 01/26/2006 | US20060020044 Methods and compositions for treating or preventing macular-degeneration related disorders |
| 01/26/2006 | US20060020043 Methods and compositions for reducing C-reactive protein |
| 01/26/2006 | US20060020042 Memantine for the treatment of mild and mild to moderate Alzheimer's disease |
| 01/26/2006 | US20060020041 substituted ethylene diamines such as N-Geranyl-N'-(2-adamanthyl)ethane-1,2-diamine, used for the treatment of leprosy or tuberculosis caused by mycobacterial infections |
| 01/26/2006 | US20060020040 Bupropion hydrochloride solid dosage forms |
| 01/26/2006 | US20060020039 E.g., 3-(2-(4-[(2-aminosulfonyl)phenyl]benzoylamino)phenoxy)benzamidine; 7-(2-(4-[(2-aminosulfonyl)phenyl]benzoylamino)-4-fluorophenoxy)1-aminoisoquinoline; and 3-(2-(4-[(2-aminosulfonyl)phenyl]phenylaminocarbonyl-4-chlorophenoxy)benzamidine; highly selective |
| 01/26/2006 | US20060020038 Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease |
| 01/26/2006 | US20060020037 Tazarotenic acid and esters thereof for treating autism |
| 01/26/2006 | US20060020036 Methods and compositions to promote bone homestasis |